News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer.
|Title||Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Chen X-H, Li Z-Q, Peng H, Jin S-M, Fu H-Q, Zhu T-C, Weng X-G|
|Journal||OncoTargets and therapy|
One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.
|Alternate Journal||Onco Targets Ther|